Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water serves as a solvent and vehicle for drug administration; it has no intrinsic pharmacological activity.
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Reconstitution of powdered medications,Dilution of intravenous medications,Flushing of intravenous lines,Hydration (when combined with electrolytes)
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
50-100 m L intravenous bolus as a vehicle for drug reconstitution or for hydration; frequency as needed for specific clinical indication.
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
1.5–3.5 hours; water turnover depends on physiological state; clinical context: equilibrates rapidly with total body water
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Not metabolized; excreted unchanged primarily by the kidneys.
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Renal: >99% as water; fecal: negligible; biliary: negligible
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
0% (water is not protein-bound)
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
0.6 L/kg (approximates total body water; Vd ~42 L in 70 kg adult)
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Intravenous: 100%; Oral: >95% (essentially complete absorption)
Intravenous: 100% (only route of administration).
No dose adjustment required; however, careful monitoring of fluid balance in patients with renal impairment to avoid fluid overload.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No dose adjustment required; sterile water does not undergo hepatic metabolism.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
Dose based on patient weight and clinical need; typical fluid maintenance: 100 m L/kg/day for first 10 kg, plus 50 m L/kg/day for next 10 kg, plus 20 m L/kg/day for weight above 20 kg; administered intravenously.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Use with caution due to potential for fluid overload; adjust volume based on renal function and cardiovascular status; typical starting dose 25-50 m L intravenous bolus.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
None.
None.
Use only sterile water for injection; hypotension and electrolyte disturbances if used in large volumes without electrolytes; hemolysis if administered intravenously without isotonicity.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Hypersensitivity to any component; do not use for intravenous injection without first making isotonic by adding solutes (except for reconstitution followed by dilution).
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
No known food interactions.
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
No known teratogenic effects in any trimester; sterile water is not pharmacologically active and does not cross the placenta in quantities that would produce fetal effects. Risk classification: FDA Category A (if considered a drug) or generally recognized as safe.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Compatible with breastfeeding; water is a normal constituent of breast milk and maternal administration does not increase risk. M/P ratio: 1.0 (approximate, as water distributes equally in body fluids).
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
No dose adjustment required; pharmacokinetics of water are unchanged in pregnancy. Standard dosing based on clinical need (e.g., hydration, dilution of medications).
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
Sterile water is used for dilution or reconstitution of medications before injection. It is not for direct intravenous administration without tonicity adjustment. Use within 2 hours after opening to minimize contamination risk.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
This product is not for direct injection; it must be mixed with medication by a healthcare professional.,Do not use if solution is cloudy or contains particulates.,Store at room temperature away from moisture and heat.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER is a Irrigation Solution that works by Water serves as a solvent and vehicle for drug administration; it has no intrinsic pharmacological activity.. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER is: 50-100 m L intravenous bolus as a vehicle for drug reconstitution or for hydration; frequency as needed for specific clinical indication.. The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER is classified as Category C. No known teratogenic effects in any trimester; sterile water is not pharmacologically active and does not cross the placenta in quantities that would produce fetal effects. Risk cl. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.